Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
Status:
Completed
Trial end date:
2021-02-08
Target enrollment:
Participant gender:
Summary
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced
or metastatic breast cancer, who have failed >/= 1 but < 5 prior lines of chemotherapy;
locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy
failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with
docetaxel (75 mg/m2) + plinabulin (40 mg) versus docetaxel (75 mg/m2) + pegfilgrastim (6 mg).
Neutrophils count will be assessed at baseline; Pre dose during Cycle 1, Day 1, 2, 6, 7, 8,
9, 10, 15.
*Study is officially closed on 08 Feb 2021*